ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)
Changes in low back pain and upper gastrointestinal symptoms in Japanese osteoporotic patients after switching to once-monthly oral minodronate from daily or weekly bisphosphonates
Nobukazu Okimoto 1, , Akinori Sakai 3 , Satoshi Ikeda 4 , Toru Yoshioka 5 , Kitau Teshima 6 , Hidehiro Matsumoto 7 , Hiroshi Tsurukami 8 , Yuichi Okazaki 9 , Masato Nagashima 10 , Fumio Fukuda 11 & Shinobu Arita 12
1Okimoto Clinic, Hiroshima, Japan; 2Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan; 3University of Occupational and Environmental Health, Fukuoka, Japan; 4Ken-Ai Memorial Hospital, Fukuoka, Japan; 5Saka Midorii Hospital, Hiroshima, Japan; 6Teshima Orthopaedic Clinic, Fukuoka, Japan; 7Sanzai Hospital, Miyazaki, Japan; 8Tsurukami Orthopaedic and Rheumatoid Clinic, Kumamoto, Japan; 9Makiyama Central Hospital, Fukuoka, Japan; 10Katsuki Neurosurgery and Orthopaedic Clinic, Fukuoka, Japan; 11Kitakyushu General Hospital, Fukuoka, Japan; 12Obase Hospital, Fukuoka, Japan.
Introduction: Minodronate, a new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. Aside from being a highly potent inhibitor of bone resorption, minodronate has been shown to possess antagonistic action against the P2X2/3 receptor, which has an important role in nociceptive transmission. The purpose of this study was to investigate the analgesic effects of once-monthly oral minodronate (MIN50 mg) on low back pain (LBP) associated with osteoporosis. We also evaluated the changes in upper gastrointestinal (GI) symptoms (common adverse effects with the use of BPs) after switching from daily or weekly BPs to MIN50 mg.
Methods: We conducted a prospective multicenter study involving 11 institutions in Japan. A total of 389 patients (367 females) using BPs for the treatment of osteoporosis were enrolled. Participants completed a self-administered questionnaire to investigate patient preference for monthly dosing regimens, and were assigned to either the MIN50 mg (n=258) or their current BP (n=131) according to their preference. Upper GI symptoms were self-assessed using a six-point symptom severity scale, and LBP was evaluated using a horizontal 100-mm visual analogue scale (VAS), for a period of 6 months.
Results: LBP VAS scores were significantly reduced in the MIN50 mg-switched group at one month post-treatment and after (P<0.001); however, no significant changes were seen in the previous BP-continued group. Upper GI symptom scores of heartburn, epigastralgia and epigastric fullness in the MIN50 mg-switched group were all significantly improved early at one month after switching, and the improvement was significantly superior compared with the previous BP-continued group (P<0.05).
Conclusion: MIN50 mg significantly improved LBP in patients previously treated with other BPs, and upper GI symptoms were significantly reduced after switching to MIN50 mg. These QOL-related benefits of MIN50 mg, together with the dosing convenience, may improve treatment adherence, thereby optimizing outcomes.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more